Trials / Approved For Marketing
Approved For MarketingNCT04100694
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Merus B.V. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual's medical history and program eligibility criteria.
Conditions
- NRG1 Fusion
- Pancreatic Cancer
- Non Small Cell Lung Cancer
- Solid Tumor, Unspecified, Adult
- Prostate Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Breast Cancer
- Cholangiocarcinoma
- Renal Cell Carcinoma
- Unknown Primary Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCLA-128 |
Timeline
- First posted
- 2019-09-24
- Last updated
- 2025-05-20
Source: ClinicalTrials.gov record NCT04100694. Inclusion in this directory is not an endorsement.